Phase II open-label study of sunitinib in patients with advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2285-0 ◽

2012 ◽

Vol 136 (3) ◽

pp. 759-767 ◽

Author(s):

Denise A. Yardley ◽

E. Claire Dees ◽

Stephen D. Myers ◽

Sherry Li ◽

Paul Healey ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Advanced Breast ◽

Open Label Study ◽

Download Full-text

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer

10.1016/j.breast.2013.03.012 ◽

2013 ◽

Vol 22 (4) ◽

pp. 470-475 ◽

Author(s):

Matteo Clavarezza ◽

Monica Turazza ◽

Enrico Aitini ◽

Silvana Saracchini ◽

Ornella Garrone ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Open Label Study ◽

Download Full-text

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.06.005 ◽

2020 ◽

Vol 20 (2) ◽

pp. 89-97 ◽

Author(s):

Denise A. Yardley ◽

William Liggett ◽

Mark Mainwaring ◽

Aurelio Castrellon ◽

Laura Blakely ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Open Label Study ◽

Label Study ◽

Hormone Receptor Positive

Download Full-text

Abstract OT2-1-08: A phase II open label study of everolimus in combination with anti-estrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer

10.1158/1538-7445.sabcs14-ot2-1-08 ◽

2015 ◽

Author(s):

Denise A Yardley ◽

Mythili Shastry ◽

Laura M DeBusk ◽

Howard A Burris III ◽

John D Hainsworth

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Estrogen Therapy ◽

Advanced Breast ◽

Open Label Study ◽

Label Study ◽

Hormone Receptor Positive

Download Full-text

A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer

Annals of Oncology ◽

10.1093/annonc/mdu064.1 ◽

2014 ◽

Vol 25 ◽

pp. i4 ◽

Author(s):

T.A. Traina ◽

D.A. Yardley ◽

M.R. Patel ◽

L.S. Schwartzberg ◽

A. Elias ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Phase 1 ◽

Advanced Breast ◽

Open Label Study ◽

Download Full-text

monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdw365.93 ◽

2016 ◽

Vol 27 ◽

pp. vi99 ◽

Author(s):

S.M. Tolaney ◽

N. Bourayou ◽

S. Goel ◽

T. Forrester ◽

F. André

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Standard Of Care ◽

Advanced Breast ◽

Phase 2 ◽

Open Label Study ◽

Download Full-text

Abstract P4-22-09: A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer

10.1158/1538-7445.sabcs16-p4-22-09 ◽

2017 ◽

Author(s):

DA Yardley ◽

L Blakely ◽

B Hemphill ◽

M Joseph ◽

W Liggett ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Hormone Receptor Positive

Download Full-text

Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study

10.1158/1538-7445.sabcs20-pd3-07 ◽

2021 ◽

Author(s):

Erika Hamilton ◽

Charles L Shapiro ◽

Daniel Petrylak ◽

Valentina Boni ◽

Miguel Martin ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Open Label Study ◽

Label Study ◽

Download Full-text

Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib*

10.1158/0008-5472.sabcs12-ot1-1-17 ◽

2012 ◽

Author(s):

T Hickish ◽

A Mehta ◽

M Jain ◽

C-S Huang ◽

N Kovalenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Open Label Study ◽

Download Full-text

Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.642 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 642-642 ◽

Author(s):

D. Slamon ◽

C. H. Yeon ◽

T. Pienkowski ◽

D. Northfelt ◽

W. Eiermann ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Advanced Breast ◽

Phase Ii Trials ◽

Randomized Phase Ii

Download Full-text

An open label phase II trial of glufosfamide: A β-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.646 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 646-646

Author(s):

G. F. Tidmarsh ◽

I. O. Kudajbergenova ◽

S. N. Navrusov ◽

V. V. Stepula

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Breast ◽

Open Label Phase ◽

Isophosphoramide Mustard

Download Full-text